BioNTech initiates global trials of mRNA-based lung cancer vaccine

BioNTech has announced the initiation of global clinical trials for BNT116, an mRNA vaccine for the potential treatment of non-small cell lung cancer (NSCLC).

The vaccine is claimed to use the same mRNA technology that proved instrumental in Covid-19 vaccines.